HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.

AbstractPURPOSE:
Combination chemotherapy results in a significant survival advantage in patients with advanced gastric cancer compared to best supportive care. Nevertheless, the prognosis remains poor with a median survival of 8-10 months. Topoisomerase-I inhibitors such as irinotecan have activity in advanced gastric cancer. Pegamotecan may offer significant advantages over other topoisomerase-I inhibitors due to its prolonged circulating half-life, tolerability and passive tumour accumulation.
PATIENTS AND METHODS:
This was a non-randomised, multi-centre, two-step Fleming design phase II study. Eligible patients with locally advanced (inoperable) or metastatic gastric or gastro-oesophageal adenocarcinoma, with measurable disease, ECOG performance status < or =2, with adequate haematological, renal and hepatic function, who had received < or =1 prior chemotherapy regimen for advanced disease, were treated with 7,000 mg/m(2) of pegamotecan as a 1-h infusion every 21 days until disease progression or unacceptable toxicity. The primary efficacy measure was the objective response rate.
RESULTS:
Five of the 35 patients recruited into this study had a partial response (14.3%), with a median time to progression of 11.9 weeks (95% CI: 6.6, 13.1), and median overall survival of 38.1 weeks (95% CI: 29.0, 47.3). Grade 3/4 toxicities included neutropenia in 6 (17.1%) patients, thrombocytopenia in 4 (11.4%), fatigue in 8 (22.9%), nausea in 6 (17%), vomiting in 6 (17%) and anorexia in 4 (11.4%) patients. There were no episodes of febrile neutropenia and no toxic deaths.
CONCLUSIONS:
Pegamotecan has activity in this patient population and was generally well-tolerated. The favourable rate of haematological toxicities and diarrhoea compared with irinotecan in similar studies suggests that pegamotecan could be combined with other active agents in further studies in this disease.
AuthorsL C Scott, J C Yao, A B Benson 3rd, A L Thomas, S Falk, R R Mena, J Picus, J Wright, M F Mulcahy, J A Ajani, T R J Evans
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 63 Issue 2 Pg. 363-70 (Jan 2009) ISSN: 1432-0843 [Electronic] Germany
PMID18398613 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Polyethylene Glycols
  • pegamotecan
  • Camptothecin
Topics
  • Adenocarcinoma (drug therapy, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Phytogenic (administration & dosage, adverse effects, therapeutic use)
  • Camptothecin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Drug Administration Schedule
  • Esophagogastric Junction (pathology)
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Polyethylene Glycols (administration & dosage, adverse effects, therapeutic use)
  • Quality of Life
  • Stomach Neoplasms (drug therapy, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: